<DOC>
	<DOCNO>NCT01979016</DOCNO>
	<brief_summary>The primary objective study assess efficacy dupilumab , compare placebo , adult patient moderate-to-severe atopic dermatitis .</brief_summary>
	<brief_title>Study Determine Safety Effectiveness Dupilumab ( REGN668/SAR231893 ) Treatment Atopic Dermatitis ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . Male female , 18 year old 2 . Chronic AD present least 3 year screen visit 3 . Patients documented recent history ( within 6 month screen visit ) inadequate response outpatient treatment topical medication , topical treatment otherwise inadvisable 4 . Willing able comply clinic visit studyrelated procedure 1 . Prior participation dupilumab clinical trial 2 . Treatment investigational drug within 8 week within 5 halflives baseline visit 3 . The following treatment within 4 week baseline visit , condition , opinion investigator , likely require treatment ( ) first 4 week study treatment : Systemic corticosteroid Immunosuppressive/immunomodulating drug Phototherapy AD 4 . Treatment topical corticosteroid , tacrolimus and/or pimecrolimus within 1 week baseline visit 5 . Treatment certain biologics 6 . Regular use ( 2 visit per week ) tan booth/parlor within 4 week baseline visit 7 . Planned major surgical procedure patient 's participation study 8 . Patient member investigational team his/her immediate family 9 . Treatment live ( attenuate ) vaccine within 12 week baseline visit 10 . Pregnant breastfeed woman woman plan become pregnant breastfeed study Note : The information list intend contain consideration relevant patient 's potential participation clinical trial therefore inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>